Figure 1

Analysis of the cytotoxic activity of Rm-HE against human cancer cell lines. (A) Cytotoxic activity of Retama monosperma Hexanic Extract (Rm-HE) in a panel of cancer and non-transformed cell lines. LN229, T98, U87, Jurkat, Jeko-1, SW620, SW480, U2OS, PC-3 and NIH3T3 cells were incubated for 48 h with 50 μg/ml of (Rm-HE); Results represent the mean ± SD of at least 3 independent experiments indicating the percentage of viable cells relative to vehicle-treated (control) cells. (B) Dose-response analysis of Retama monosperma Hexanic Extract (Rm-HE) and IC₅₀ determination on Jurkat cells. Cells were treated with Rm-HE for 48 h at different concentrations ranging from 1 to 50 μg/ml; IC₅₀ value (μg/ml) was determined graphically from the viability curves, NIH3T3 and TK6 cells were used as control. Data are expressed as means ± SD of triplicate determinations.